Novo Nordisk A/S saw a 40% surge in sales of its diabetes and weight-loss drugs in India last month, after steep price cuts boosted demand for its branded treatments even as generic GLP-1 therapies flood the market. For the full story, visit the source.
Business
Novo Nordisk’s Ozempic India Price Cut Boosts Obesity Drug Sales
Novo Nordisk A/S saw a 40% surge in sales of its diabetes and weight-loss drugs in India last month, after steep price cuts boosted demand for its branded treatments even as generic GLP-1 therapies flood the market.
By Bloomberg News· Financial Post· 1 day ago· 2 min read
This summary is sourced from Financial Post. Read the full article at:Financial Post